All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
GvHD Hub Chair Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR, provides the highlights for GvHD from the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
ASH 2020: Highlights for GvHD
Mohty focuses on topics that, in his opinion, will make an important difference in the management of chronic GvHD. He underlines key findings from studies evaluating ruxolitinib and the novel agent belumosudil (KD025) for the treatment of chronic GvHD.
Editorial Theme | Novel therapies for the treatment of GvHD
Currently, there are only two approved treatments for GvHD: ruxolitinib, indicated for steroid resistant (SR) aGvHD, and ibrutinib, used in patients with cGvHD who have failed one or more...
Editorial theme | Latest updates on cGvHD treatment
First-line treatment for chronic graft-versus-host disease (cGvHD), which consists of steroids, has not changed much over the last three decades. In the case of severe cGvHD, another...
Subscribe to get the best content related to GvHD delivered to your inbox